ADAM15 drives venetoclax resistance via HCK–AKT–FOXO3A signaling in AML

Abstract excerpt

<title>Abstract</title> <p>Venetoclax-based regimens have improved outcomes in acute myeloid leukemia (AML), but resistance frequently emerges and limits durable benefit. The upstream signaling mechanisms linking therapeutic stress to apoptotic evasion remain poorly defined. Here, we identify ADAM15 as a previously unrecognized regulator of venetoclax resistance in AML. Integrative multi-omics analyses across exp...

Topics

Open a Topic to create a Post that cites this publication.

• Acute Myeloid Leukemia Research
• Antineoplastic Combined Chemotherapy Protocols
• Bridged Bicyclo Compounds, Heterocyclic
• Drug Resistance, Neoplasm
• Histone Deacetylase Inhibitors Research
• Leukemia, Myeloid, Acute
• Protein Degradation and Inhibitors
• Proto-Oncogene Proteins c-bcl-2

Identifiers and source

Literature Corpus work

7f53dc65-7e76-56ae-a443-ddcc777b3261

DOI

10.21203/rs.3.rs-9498017/v1